U.S. Markets closed
  • S&P 500

    4,158.24
    +100.40 (+2.47%)
     
  • Dow 30

    33,212.96
    +575.77 (+1.76%)
     
  • Nasdaq

    12,131.13
    +390.48 (+3.33%)
     
  • Russell 2000

    1,887.90
    +49.66 (+2.70%)
     
  • Crude Oil

    115.07
    +0.98 (+0.86%)
     
  • Gold

    1,850.60
    +3.00 (+0.16%)
     
  • Silver

    22.14
    +0.17 (+0.77%)
     
  • EUR/USD

    1.0739
    +0.0006 (+0.0537%)
     
  • 10-Yr Bond

    2.7430
    -0.0130 (-0.47%)
     
  • Vix

    25.72
    -1.78 (-6.47%)
     
  • GBP/USD

    1.2631
    +0.0025 (+0.2021%)
     
  • USD/JPY

    127.0850
    -0.0170 (-0.0134%)
     
  • BTC-USD

    28,843.02
    -120.51 (-0.42%)
     
  • CMC Crypto 200

    625.79
    -3.71 (-0.59%)
     
  • FTSE 100

    7,585.46
    +20.54 (+0.27%)
     
  • Nikkei 225

    26,781.68
    +176.84 (+0.66%)
     
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Why you should get a booster even though you could still get Omicron: Scientist

·Senior Reporter
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Though COVID-19 vaccines and boosters provide strong protection against severe disease, hospitalizations, and deaths, the quickly-spreading Omicron variant remains a significant challenge. With a daily average of more than 750,000 cases in the U.S., some doubt the vaccines' effectiveness and wonder, 'Why get the booster if I can still get infected?"

But Dr. Eric Topol, founder and director of the Scripps Research Translational Institute, said people's doubts are misplaced.

"The Omicron variant provides "a 90% reduction of hospitalizations," Topol said, adding that after three months that number can drop to 80%.

That is still comparable to two doses versus the original strain, Topol said.

Third doses of Pfizer (PFE)/BioNTech's (BNTX) and Moderna (MRNA)'s shots — both mRNA vaccines — have shown strong results against Omicron. And Johnson & Johnson's (JNJ) has shown its two doses are able to hold durable protection over a long period of time.

But because the U.S. has a low booster rate, the Omicron variant is affecting more people, though overall the strain is milder compared to previous variants. It's why hospitalizations continue to strain the country's health care systems, setting new records daily, with more than 159,000 individuals in hospitals now, according to the CDC.

Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, recently told Yahoo Finance that ongoing protection from vaccines is why the U.S. is holding off on fourth doses for now — except for in the case of immunocompromised individuals.

Israel has already tested fourth doses, and a recent report shows it isn't providing significant protection. Fauci said the U.S. needs to understand the durability of protection from a third dose before weighing a fourth.

Topol noted that in the Israeli study it is unclear what level of protection against hospitalization and death the fourth dose provides, but that data will become available in coming weeks.

Follow Anjalee on Twitter @AnjKhem

Read the latest financial and business news from Yahoo Finance

Follow Yahoo Finance on Twitter, Instagram, YouTube, Facebook, Flipboard, and LinkedIn